Drug Resistance
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Drug Resistance, Neoplasm
Drug Resistance, Viral
Drug Resistance, Multiple
Drug Resistance, Microbial
Drug Resistance, Bacterial
Drug Resistance, Multiple, Bacterial
Drug Resistance, Fungal
Mutation
Microbial Sensitivity Tests
Neoplasms
Disease Resistance
Drug Resistance, Multiple, Viral
P-Glycoprotein
A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).
Vascular Resistance
Antitubercular Agents
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
Anti-HIV Agents
HIV-1
Molecular Sequence Data
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Antimalarials
HIV Protease
Genotype
Multidrug Resistance-Associated Proteins
A sequence-related subfamily of ATP-BINDING CASSETTE TRANSPORTERS that actively transport organic substrates. Although considered organic anion transporters, a subset of proteins in this family have also been shown to convey drug resistance to neutral organic drugs. Their cellular function may have clinical significance for CHEMOTHERAPY in that they transport a variety of ANTINEOPLASTIC AGENTS. Overexpression of proteins in this class by NEOPLASMS is considered a possible mechanism in the development of multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although similar in function to P-GLYCOPROTEINS, the proteins in this class share little sequence homology to the p-glycoprotein family of proteins.
Neoplasms, Cystic, Mucinous, and Serous
HIV Infections
HIV Reverse Transcriptase
A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process.
Mycobacterium tuberculosis
R Factors
ATP-Binding Cassette Transporters
Genes, MDR
Tetracycline Resistance
Doxorubicin
Drug Resistance, Multiple, Fungal
Streptomycin
Neoplasm Proteins
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tetracycline
Reverse Transcriptase Inhibitors
Isoniazid
Sequence Analysis, DNA
Chloroquine
Phenotype
Polymerase Chain Reaction
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Base Sequence
Ovarian Neoplasms
Parasitic Sensitivity Tests
Rifampin
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Plasmodium falciparum
Neoplasms, Multiple Primary
Escherichia coli
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
Airway Resistance
Tumor Cells, Cultured
Mutation, Missense
Conjugation, Genetic
A parasexual process in BACTERIA; ALGAE; FUNGI; and ciliate EUKARYOTA for achieving exchange of chromosome material during fusion of two cells. In bacteria, this is a uni-directional transfer of genetic material; in protozoa it is a bi-directional exchange. In algae and fungi, it is a form of sexual reproduction, with the union of male and female gametes.
Apoptosis
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Pyrimethamine
Plasmids
Membrane Transport Proteins
Gene Expression Regulation, Neoplastic
Kanamycin
Neoplasms, Second Primary
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
beta-Lactam Resistance
Amino Acid Sequence
HIV Protease Inhibitors
Treatment Failure
Resistance Training
A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
Immunohistochemistry
Cell Survival
Chloramphenicol Resistance
Inhibitory Concentration 50
Reverse Transcriptase Polymerase Chain Reaction
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
Adenocarcinoma, Mucinous
Signal Transduction
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Sulfadoxine
Drug Screening Assays, Antitumor
Ampicillin Resistance
Myeloproliferative Disorders
Antifungal Agents
Antibiotics, Antineoplastic
Tetrahydrofolate Dehydrogenase
An enzyme of the oxidoreductase class that catalyzes the reaction 7,8-dihyrofolate and NADPH to yield 5,6,7,8-tetrahydrofolate and NADPH+, producing reduced folate for amino acid metabolism, purine ring synthesis, and the formation of deoxythymidine monophosphate. Methotrexate and other folic acid antagonists used as chemotherapeutic drugs act by inhibiting this enzyme. (Dorland, 27th ed) EC 1.5.1.3.
pol Gene Products, Human Immunodeficiency Virus
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Neoplasms, Experimental
Immunity, Innate
Cisplatin
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Ethambutol
An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
Dose-Response Relationship, Drug
Drug Combinations
Erythromycin
A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.
P-Glycoproteins
A subfamily of transmembrane proteins from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS that are closely related in sequence to P-GLYCOPROTEIN. When overexpressed, they function as ATP-dependent efflux pumps able to extrude lipophilic drugs, especially ANTINEOPLASTIC AGENTS, from cells causing multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although P-Glycoproteins share functional similarities to MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS they are two distinct subclasses of ATP-BINDING CASSETTE TRANSPORTERS, and have little sequence homology.
Treatment Outcome
Dihydropteroate Synthase
Chloramphenicol
An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)
RNA, Messenger
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Cystadenoma
Neoplasms, Connective and Soft Tissue
Neoplasms, Plasma Cell
Point Mutation
Prevalence
Anti-Infective Agents
Antineoplastic Agents, Phytogenic
Candida albicans
Methicillin Resistance
Models, Biological
Tumor Markers, Biological
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Cystadenoma, Mucinous
Neoplasms, Glandular and Epithelial
DNA Primers
Carcinoma, Pancreatic Ductal
Gastrointestinal Neoplasms
Antigens, Neoplasm
Artemisinins
Fluconazole
Vault Ribonucleoprotein Particles
Drug Therapy, Combination
Tuberculosis
beta-Lactamases
Extrachromosomal Inheritance
Vancomycin Resistance
Blotting, Western
Staphylococcus aureus
Neoplasm Staging
DNA Gyrase
A bacterial DNA topoisomerase II that catalyzes ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. Gyrase binds to DNA as a heterotetramer consisting of two A and two B subunits. In the presence of ATP, gyrase is able to convert the relaxed circular DNA duplex into a superhelix. In the absence of ATP, supercoiled DNA is relaxed by DNA gyrase.
Macrolides
Pyrimidines
Neoplasms, Vascular Tissue
Insulin
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
Daunorubicin
Gene Expression Profiling
Viral Load
Ampicillin
Neoplasms, Radiation-Induced
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Neoplastic Stem Cells
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
Cloning, Molecular
Antiretroviral Therapy, Highly Active
Testicular Neoplasms
Gene Expression
Transfection
Carcinoma, Papillary
Adenocarcinoma, Papillary
DNA Transposable Elements
Discrete segments of DNA which can excise and reintegrate to another site in the genome. Most are inactive, i.e., have not been found to exist outside the integrated state. DNA transposable elements include bacterial IS (insertion sequence) elements, Tn elements, the maize controlling elements Ac and Ds, Drosophila P, gypsy, and pogo elements, the human Tigger elements and the Tc and mariner elements which are found throughout the animal kingdom.
Nevirapine
Extensively Drug-Resistant Tuberculosis
Kanamycin Resistance
Neoplasm Metastasis
Alleles
Neoplasms, Muscle Tissue
Dog Diseases
Gene Amplification
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Folic Acid Antagonists
Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. (1/9539)
Human melanoma cell lines derived from early stage primary tumors are particularly sensitive to growth arrest induced by interleukin-6 (IL-6). This response is lost in cell lines derived from advanced lesions, a phenomenon which may contribute to tumor aggressiveness. We sought to determine whether resistance to growth inhibition by IL-6 can be explained by oncogenic alterations in cell cycle regulators or relevant components of intracellular signaling. Our results show that IL-6 treatment of early stage melanoma cell lines caused G1 arrest, which could not be explained by changes in levels of G1 cyclins (D1, E), cdks (cdk4, cdk2) or by loss of cyclin/cdk complex formation. Instead, IL-6 caused a marked induction of the cdk inhibitor p21WAF1/CIP1 in three different IL-6 sensitive cell lines, two of which also showed a marked accumulation of the cdk inhibitor p27Kip1. In contrast, IL-6 failed to induce p21WAF1/CIP1 transcript and did not increase p21WAF1/CIP1 or p27kip1 proteins in any of the resistant lines. In fact, of five IL-6 resistant cell lines, only two expressed detectable levels of p21WAF1/CIP1 mRNA and protein, while in three other lines, p21WAF1/CIP1 was undetectable. IL-6 dependent upregulation of p21WAF1/CIP1 was associated with binding of both STAT3 and STAT1 to the p21WAF1/CIP1 promoter. Surprisingly, however, IL-6 stimulated STAT binding to this promoter in both sensitive and resistant cell lines (with one exception), suggesting that gross deregulation of this event is not the unifying cause of the defect in p21WAF1/CIP1 induction in IL-6 resistant cells. In somatic cell hybrids of IL-6 sensitive and resistant cell lines, the resistant phenotype was dominant and IL-6 failed to induce p21WAF1/CIP1. Thus, our results suggest that in early stage human melanoma cells, IL-6 induced growth inhibition involves induction of p21WAF1/CIP1 which is lost in the course of tumor progression presumably as a result of a dominant oncogenic event. (+info)Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. (2/9539)
Primary blasts of a t(11;17)(q23;q21) acute promyelocytic leukaemia (APL) patient were analysed with respect to retinoic acid (RA) and arsenic trioxide (As2O3) sensitivity as well as PLZF/RARalpha status. Although RA induced partial monocytic differentiation ex vivo, but not in vivo, As203 failed to induce apoptosis in culture, contrasting with t(15;17) APL and arguing against the clinical use of As203 in t(11;17)(q23;q21) APL. Prior to cell culture, PLZF/RARalpha was found to exactly co-localize with PML onto PML nuclear bodies. However upon cell culture, it quickly shifted towards microspeckles, its localization found in transfection experiments. Arsenic trioxide, known to induce aggregation of PML nuclear bodies, left the microspeckled PLZF/RARalpha localization completely unaffected. RA treatment led to PLZF/RARalpha degradation. However, this complete PLZF/RARalpha degradation was not accompanied by differentiation or apoptosis, which could suggest a contribution of the reciprocal RARalpha/PLZF fusion product in leukaemogenesis or the existence of irreversible changes induced by the chimera. (+info)Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (3/9539)
Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals. (+info)Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. (4/9539)
To elucidate the mechanisms involved in anti-oestrogen resistance, two human breast cancer cell lines MCF-7 and the ICI 182780-resistant cell line, MCF-7/182R-6, have been compared with regard to oestrogen receptor (ER) expression, ER function, ER regulation, growth requirements and differentially expressed gene products. MCF-7/182R-6 cells express a reduced level of ER protein. The ER protein is functional with respect to binding of oestradiol and the anti-oestrogens tamoxifen, 4-hydroxy-tamoxifen and ICI 182780, whereas expression and oestrogen induction of the progesterone receptor is lost in MCF-7/182R-6 cells. The ER protein and the ER mRNA are regulated similarly in the two cell lines when subjected to treatment with oestradiol or ICI 182780. Oestradiol down-regulates ER mRNA and ER protein expression. ICI 182780 has no initial effect on ER mRNA expression whereas the ER protein level decreases rapidly in cells treated with ICI 182780, indicating a severely decreased stability of the ER protein when bound to ICI 182780. In vitro growth experiments revealed that the ICI 182780-resistant cell line had evolved to an oestradiol-independent phenotype, able to grow with close to maximal growth rate both in the absence of oestradiol and in the presence of ICI 182780. Comparison of gene expression between the two cell lines revealed relatively few differences, indicating that a limited number of changes is involved in the development of anti-oestrogen resistance. Identification of the differentially expressed gene products are currently in progress. (+info)p53 status of newly established acute myeloid leukaemia cell lines. (5/9539)
We analysed the status of the p53 gene and protein in eight newly established acute myeloid leukaemia (AML) cell lines representing blast cells of either de novo leukaemia patients in first remission or patients with relapsed and chemotherapy-resistant disease causing their death. There were no mutations in the p53 gene in any of the cell lines as analysed by single-strand conformation polymorphism of amplified exons 5-8. However, the p53 protein was clearly and consistently expressed in all of these cell lines, as shown by immunohistochemistry, Western blotting and flow cytometry. The consistently expressed p53 protein was located in both the nucleus and the cytoplasm of all the cell lines and, as shown by flow cytometry, it was mostly in a conformation typical of the mutated protein. These AML cell lines offer a tool for studying the production and function of the p53 protein and its possible role in cell cycle regulation and chemoresistance as well as in the regulation of apoptosis in AML. (+info)Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (6/9539)
Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency. (+info)SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. (7/9539)
Resistance to chemotherapy is the major cause of cancer treatment failure. Insight into the mechanism of action of agents that modulate multidrug resistance (MDR) is instrumental for the design of more effective treatment modalities. Here we show, using KB-V-1 MDR human epidermoid carcinoma cells and [3H]palmitic acid as metabolic tracer, that the MDR modulator SDZ PSC 833 (PSC 833) activates ceramide synthesis. In a short time course experiment, ceramide was generated as early as 15 min (40% increase) after the addition of PSC 833 (5.0 microM), and by 3 h, [3H]ceramide was >3-fold that of control cells. A 24-h dose-response experiment showed that at 1.0 and 10 microM PSC 833, ceramide levels were 2.5- and 13.6-fold higher, respectively, than in untreated cells. Concomitant with the increase in cellular ceramide was a progressive decrease in cell survival, suggesting that ceramide elicited a cytotoxic response. Analysis of DNA in cells treated with PSC 833 showed oligonucleosomal DNA fragmentation, characteristic of apoptosis. The inclusion of fumonisin B1, a ceramide synthase inhibitor, blocked PSC 833-induced ceramide generation. Assessment of ceramide mass by TLC lipid charring confirmed that PSC 833 markedly enhanced ceramide synthesis, not only in KB-V-1 cells but also in wild-type KB-3-1 cells. The capacity of PSC 833 to reverse drug resistance was demonstrated with vinblastine. Whereas each agent at a concentration of 1.0 microM reduced cell survival by approximately 20%, when PSC 833 and vinblastine were coadministered, cell viability fell to zero. In parallel experiments measuring ceramide metabolism, it was shown that the PSC 833/vinblastine combination synergistically increased cellular ceramide levels. Vinblastine toxicity, also intensified by PSC 833 in wild-type KB-3-1 cells, was as well accompanied by enhanced ceramide formation. These data demonstrate that PSC 833 has mechanisms of action in addition to P-glycoprotein chemotherapy efflux pumping. (+info)Modulation of the cytotoxicity of 3'-azido-3'-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: identification of a correlation between folate receptor expression and thymidine kinase activity. (8/9539)
Cervical carcinoma is an AIDS-defining illness. The expression of folate receptors (FRs) in cervical carcinoma (HeLa-IU1) cells was modulated by stable transduction of FR cDNA encapsidated in recombinant adeno-associated virus-2 in the sense and antisense orientation (sense and antisense cells, respectively). Although sense cells proliferated slower than antisense or untransduced cells in vivo and in vitro in 2% (but not 10%) FCS, [methyl-3H]thymidine incorporation into DNA was significantly increased in sense cells in 10% serum; therefore, the basis for this discrepancy was investigated. The activity of thymidine kinase (TK) was subsequently directly correlated with the extent of FR expression in single cell-derived clones of transduced cells. This elevated TK activity was not a result of recruitment of the salvage pathway based on the presence of adequate dTTP pools, normal thymidylate synthase (TS) activity, persistence of increased thymidine incorporation despite the exogenous provision of excess 5,10-methylene-tetrahydrofolate, and documentation of adequate folates in sense cells. The increase in TK activity conferred significant biological properties to sense cells (but not antisense or untransduced cells) as demonstrated by augmented phosphorylation of 3'-azido-3'-deoxythymidine (AZT) and concomitantly greater sensitivity to the cytotoxic effects of AZT. Conversely, sense cells were highly resistant to methotrexate, but this was reversed by the addition of AZT. The direct correlation of FR expression and TK activity indicates a previously unrecognized consequence of FR overexpression. (+info)Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance - pdf descargar
BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance
Pathological transition as the arising mechanism for drug resistance in lung cancer | Cancer Communications | Full Text
How to deal with cancer drug resistance - Research Idea, Design and Collaboration - BioForum
Cancer Drug Resistance
Research and Markets: This Essential Report on Cancer Drug Resistance is Available Now. - Free Online Library
Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer...
Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro |...
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug - CSHL Scientific...
Novel Treatment to Overpower Ovarian Cancer Drug Resistance
JCI -
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance
Genetic Targets for Chemo-resistant Breast Cancer Identified
AACR 2019 Research Roundup: Pancreatic Cancer Immunotherapy, Prostate Cancer Drug Resistance, Insight into Inherited Cancer...
New Genes for Nothing, Drug Resistance for Free
Protein-analysis] How many passages takes to obtain mutants in a
cell line?
Bacteria contribute to chemotherapy resistance
Successful cancer remission. Client says, I have stumped my white coats again and again and again and again using EFT. |...
Plus it
New Approach to Screening Chemo Drugs | Chemotherapy
Browsing Advanced Reasoning Group by Author Vander Heyden, Yvan
Identification Of Culprit Behind Chemotherapy Resistance in Cancer
Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its...
EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer | BMC Cancer |...
Therapy resistance mediated by exosomes | Molecular Cancer | Full Text
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer - Full Text View...
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression<...
Frontiers | Molecular determinants of sensitivity or resistance of cancer cells towards sanguinarine | Pharmacology
Defining the molecular transcriptomic profile for predicting the clinical outcome of anthracycline resistant breast cancers....
Molecular determinants of sensitivity or resistance of cancer cells toward sanguinarine<...
Can FDA-Approved HIV Drugs Treat Chemoresistant Ovarian Cancer? | Libbys H*O*P*E*
Hypersecretion of fibroblast-derived exosomes during chemotherapy promotes pancreatic cancer chemoresistance
New peptides to fight ovarian cancer drug resistance - academics
Gene expression profile associated with docetaxel resistance in breast cancer cells<...
Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. - PubMed - NCBI
A2780cis
February: lung cancer drug resistance | News | University of Bristol
Isolation and characterization of chemoresistant canine tumor cells
Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage...
Model of tumor cell resistance to antineoplastic therap | Open-i
Plus it
Gene expression predicts chemotherapy sensitivity of triple-negative bre... ( German researchers have identified a...)
Plus it
Plus it
Molecular determinants of chemotherapy resistance in ovarian cancer<...
Scientists Develop Mathematical Model to Predict Cancer Cells Resistance to Therapy - The ASCO Post
The KHIT Blog: September 2018
Plus it
Regular in vitro medication testing uses 2-D tissues lifestyle plate systems - Synthetic Small Molecule Inhibitors of Hh...
Desktop Genetics, Imperial College London Receive $430K Grant to Build CRISPR Software | GenomeWeb
KAKEN - Researchers | GOMI Katsuya (60302197)
Researchers investigate drug resistant ovarian cancer to improve clinical treatment
The role of extra DNA in cancer evolution and therapy resistance
Integrative Personal Omics Profiles in Glioblastoma Recurrence and Therapy Resistance | International Research Projects | IIS...
MOR/0.2R | Creative Bioarray
Understanding and targeting resistance mechanisms in NSCLC. - NextBio article
Plus it
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer (REPROVe) :: Val-083 Clinical...
Reversal of cisplatin resistance in vivo by an anti-fos ribozyme - Fingerprint - Tohoku University
In the third case, we were unable to create a definitive determin | Peptide Cost
Soft drug-resistant ovarian cancer cells migrate via two distinct mechanisms utilizing myosin II-based contractility. -...
Cardiac arrhythmogenesis is a major clinical problem. - Physiology, Anatomy and Genetics
Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death
New Electronic Books Available (March) | Highlights from Graff Library
November 2017 - Effect of BET Missense Mutations on Bromodomain Function
Omega-3 Fats Help Overcome Multi-Drug Resistant Cancer | GreenMedInfo
Metabolic contribution to cell viability and therapy resistance in the acute - Timothy Pardee
Diagnosis and Screening in Colorectal Cancer | SpringerLink
Reduced microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2 - 臺北醫學大學
Novel Mechanism of Resistance to Anti-Cancer Drugs - Tasnim News Agency
Resistance is not useless | How to study effectively
Trophoblastic neoplasm
... targeted cancer therapies would be capable of improving the therapeutic perspective among patients with drug resistance. ...
PDGFRB
Primary or acquired drug resistance to this drug is very rare. Additional adjuvant chemotherapy may be necessary if a patients ... This continuous signaling, it is presumed, leads to the development of myeloid and/or lymphoid neoplasms that commonly include ... The drug often causes long-term complete hematological and cytogenic remissions as doses well below those used to treat chronic ... The disease is treated with a chemotherapy drug, lenalidomide. Human chromosome translocations between the PDGFRB gene and at ...
Clonal hypereosinophilia
... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... This resistance is linked to the occurrence of a S601P mutation in PDGFRA. Acquired resistance to imatinib have in most cases ... That is, many types of these disorders are remarkably susceptible to relatively non-toxic drugs. Hematopoietic stem cells give ... Like the latter neoplasm, hematologic neoplasms cause by ETV6-JAK2 and BCR-JAK2 are aggressive and progress rapidly. Too few ...
Somatic evolution in cancer
Sequential application of drugs can lead to the sequential evolution of resistance mutations to each drug in turn. Gleevec is ... which may be benign neoplasms) or else a malignant neoplasm (cancer). These neoplasms are also indicated, in the diagram below ... However, most patients' tumors eventually become resistant to these drugs. Two major mechanisms of acquired resistance have ... Schimke RT (May 1984). "Gene amplification, drug resistance, and cancer". Cancer Research. 44 (5): 1735-1742. PMID 6713376. ...
Cobimetinib
... and for histiocytic neoplasms in 2021. Acquired resistance to BRAF inhibitors, such as vemurafenib and dabrafenib, commonly ... "Cobimetinib Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 26 April 2021. Retrieved 4 July ... "Drug Trials Snapshots: Cotellic". U.S. Food and Drug Administration (FDA). 30 July 2020. Retrieved 21 September 2021. This ... "Cobimetinib Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 31 January 2014. Retrieved 4 July ...
C-peptide
Creative Peptides, Eli Lilly, and Cebix all had drug development programs for a C-peptide product. Cebix had the only ongoing ... C-peptide may be used for determining the possibility of gastrinomas associated with Multiple Endocrine Neoplasm syndromes (MEN ... to help determine degree of insulin resistance. Therapeutic use of C-peptide has been explored in small clinical trials in ... Bigelow BV (23 February 2015). "Cebix Shuts Down Following Mid-Stage Trial of C-Peptide Drug". Xconomy. Garde D (February 24, ...
Nerve sheath tumor
Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small ... A nerve sheath tumor is a type of tumor of the nervous system (nervous system neoplasm) which is made up primarily of the ... From benign tumors like schwannoma to high grade malignant neoplasms known as malignant peripheral nerve sheath tumors, ... PubMed: 6310227] Carroll S. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 2012 ...
Lung cancer
Spaans JN, Goss GD (August 2014). "Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and ... Recurrence of lung cancer Horn L, Lovly CM (2018). "Chapter 74: Neoplasms of the lung". In Jameson JL, Fauci AS, Kasper DL, ... Clinical trials are underway to evaluate how well these drugs kill lung cancer cells in humans. Several drugs that target ... Targeting these tags with drugs can kill cancer cells. Early-stage research in NSCLC using drugs aimed at epigenetic ...
Vemurafenib
"Researchers Uncover Drug-Resistance Mechanisms in BRAF Melanoma". Genetic Engineering & Biotechnology News. November 25, 2010. ... a rare type of histiocytic neoplasm. Vemurafenib causes programmed cell death in melanoma cell lines. Vemurafenib interrupts ... Drug has EMA link, Antineoplastic and immunomodulating drugs, B-Raf inhibitors, Chloroarenes, Fluoroarenes, Sulfonamides, ... "Drug hope for advanced melanoma". BBC News. 2009-06-02. Retrieved 2009-06-07. Harmon, Amy (2010-02-21). "A Roller Coaster Chase ...
List of MeSH codes (G12)
... drug resistance, multiple, viral MeSH G12.392.395 - drug resistance, neoplasm MeSH G12.392.491 - insecticide resistance MeSH ... drug resistance, fungal MeSH G12.392.269.383.500 - drug resistance, multiple, fungal MeSH G12.392.269.420 - drug resistance, ... drug resistance, multiple, viral MeSH G12.392.300 - drug resistance, multiple MeSH G12.392.300.500 - drug resistance, multiple ... herb-drug interactions MeSH G12.392.269 - drug resistance, microbial MeSH G12.392.269.347 - drug resistance, bacterial MeSH ...
Oncogenomics
Metastasis and drug resistance are distinguishable. Access to methylation profiling is important to cancer research because: ... caused by accumulation of DNA mutations and epigenetic alterations leading to unrestrained cell proliferation and neoplasm ... Drug therapies can inhibit PIK3CA. Another example is the BRAF gene, one of the first to be implicated in melanomas. BRAF ... Some anticancer drugs target mtDNA and have shown positive results in killing tumor cells. Research has used mitochondrial ...
Ubiquitin
Dou QP, Li B (August 1999). "Proteasome inhibitors as potential novel anticancer agents". Drug Resistance Updates. 2 (4): 215- ... Kales SC, Ryan PE, Nau MM, Lipkowitz S (June 2010). "Cbl and human myeloid neoplasms: the Cbl oncogene comes of age". Cancer ... Vries EG, Verweij J (2000). "Clinical Cancer Research 2000: New Agents and Therapies". Drug Resistance Updates. 3 (4): 197-201 ... Drug Resistance Updates. 5 (6): 249-58. doi:10.1016/s1368-7646(02)00121-8. PMID 12531181. Clifford SC, Cockman ME, Smallwood AC ...
Regulation of transcription in cancer
Chen HY, Shao CJ, Chen FR, Kwan AL, Chen ZP (2010). "Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in ... Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms). Thus, CpG island hyper/hypo- ...
Arginylglycylaspartic acid
Active targeting strategies aim to increase drug transport into cells to improve efficacy and counter multidrug resistance. In ... Bone defects or fractures can occur in a number of ways, including trauma, neoplasm, osteoporosis, or congenital disorders. ... increasing concentration of the drug at the site of action and decreasing drug concentration elsewhere, thereby increasing the ... clinical use and new drugs". Nature Reviews Drug Discovery. 15 (3): 173-183. doi:10.1038/nrd.2015.10. PMC 4890615. PMID ...
Pancreatic disease
Cysts also may be present due to intraductal papillary mucinous neoplasm. Pancreas divisum is a malformation in which the ... Type 2 diabetes mellitus, which begins with insulin resistance, is characterized by the ultimate failure of pancreatic β cells ... Less frequent but important causes are hypertriglyceridemia, drugs, infections. Chronic pancreatitis is a long-standing ... Pancreatic tumors (masses) including pancreatic cancer Serous cystadenoma of the pancreas Solid pseudopapillary neoplasm ...
List of MeSH codes (G04)
... drug resistance, viral MeSH G04.185.515.286.420.500 - drug resistance, multiple, viral MeSH G04.185.515.329 - drug resistance, ... neoplasm regression, spontaneous MeSH G04.335.119.260 - erythrocyte aging MeSH G04.335.122.100 - autocrine communication MeSH ... vancomycin resistance MeSH G04.185.515.286.383 - drug resistance, fungal MeSH G04.185.515.286.383.500 - drug resistance, ... drug resistance, multiple, fungal MeSH G04.185.515.329.750 - drug resistance, multiple, viral MeSH G04.185.515.372 - germ-free ...
Philadelphia chromosome
Axitinib, a drug used to treat renal cell carcinoma, has been shown to be effective at inhibiting the Abl kinase activity in ... JAK2 mutations have been shown to be central to myeloproliferative neoplasms and JAK kinases play a central role in driving ... Combination therapies with nilotinib and ruxolitnib have also shown success in suppressing resistance by targeting the JAK-STAT ... In apoptotic inhibition, BCR-ABL cells have been shown to be resistant to drug-induced apoptosis but also have a proapoptotic ...
Downregulation and upregulation
This is the more common process of insulin resistance, which leads to adult-onset diabetes. Another example can be seen in ... This occurs, for instance, during drug addiction or progression to cancer. All living cells have the ability to receive and ... Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms).[verification needed] Investigation ... The disequilibrium caused by these changes often causes withdrawal when the long-term use of a drug is discontinued. ...
Beverly Mock
Mock, Beverly A.; Nacy, C. A. (December 1988). "Hormonal modulation of sex differences in resistance to Leishmania major ... "Interleukin 6 is essential for in vivo development of B lineage neoplasms". Journal of Experimental Medicine. 182 (1): 243-248 ... traits associated with cancer initiation and progression in an effort to develop strategies for identifying and analyzing drug ...
VAMP regimen
Combining multiple chemotherapeutic drugs into one treatment helps overcome the problem of drug resistance. Furthermore, ... McKay, Lorraine I.; Cidlowski, John A. (2003). "Corticosteroids in the Treatment of Neoplasms". {{cite journal}}: Cite journal ... Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 15 (5-6): 249-257. doi:10.1016/ ... Vincristine is a drug isolated from the Madagascar periwinkle, first discovered by the Eli Lilly company in 1958 in a search ...
BRAF (gene)
February 2013). "Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance". Nature. 494 ( ... a benign but locally infiltrative odontogenic neoplasm. The V600E mutation may also be linked, as a single-driver mutation (a ... In spite of the drug's high efficacy, 20% of tumors still develop resistance to the treatment. In mice, 20% of tumors become ... Drugs that treat cancers driven by BRAF mutations have been developed. Two of these drugs, vemurafenib and dabrafenib are ...
Boil
... lymphoproliferative neoplasms, malnutrition, and use of immunosuppressive drugs. People with recurrent boils are as well more ... It may occur following antibiotic use due to the development of resistance to the antibiotics used. An associated skin disease ... Knowledge of the antimicrobial resistance of S. aureus is important in the selection of antimicrobials for treatment. Nodule ( ... Laube S, Farrell M (2002). "Bacterial skin infection in the elderly: diagnosis and treatment". Drugs & Aging. 19 (5): 331-42. ...
Host-pathogen interaction
The main problem with pathogenic drug treatments in the modern world is drug resistance. Many patients don't take the full ... "Integrated pan-cancer map of EBV-associated neoplasms reveals functional host-virus interactions". Cancer Research. 79 (23): ... only the bacteria which have developed genetic mutations to combat the drug can survive. This reduces drug effectiveness and ... These drugs are specifically designed to kill microbes or inhibit further growth within the host environment. Multiple terms ...
Hyperinsulinemia
Studies have shown that the high levels of insulin resulting from insulin resistance might enhance insulin resistance. Studies ... Hyperinsulinemia can be seen in a variety of conditions including diabetes mellitus type 2, in neonates and in drug-induced ... Neoplasm Carbohydrate malabsorption Pancreatic cancer Polycystic ovary syndrome (PCOS) Trans fats Since hyperinsulinemia and ... Shanik, M.H.; Yuping, X.; Skrha, J.; Danker, R.; Zick, Y.; Roth, J. (2008). "Insulin Resistance and Hyperinsulinemia". Diabetes ...
H19 (gene)
Curiously, mutant revertant MCF-7/AdrVp cells that lost their multidrug resistance and became drug-sensitive also lost H19 ... In contrast to most other cancers, adrenocortical neoplasms appear to have decreased expression of H19. To determine a possible ... Drug-resistant MCF-AdrVp cells do not overexpress P-glycoprotein, a cell membrane efflux pump commonly found in multidrug ... p95, or NCA-90, is related to carcinoembryonic antigens, which have been found to reduce drug toxicity by Kawaharata et al. NCI ...
Mir-708 microRNA precursor family
"A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the ... "miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets ...
FIP1L1
Acquired resistance to Gleevec is uncommon but has been observed in patients whose mutated cells develop a T674I or D842V ... This drug, also known as Gleevec, has been a FDA-approved and most successful treatment for Philadelphia chromosome-positive ... Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN (2015). "Hematolymphoid neoplasms associated with rearrangements of ... While the success of Gleevec in treating the myeloproliferative neoplasm/myeloblastic leukemia or T-lymphoblastic leukemia/ ...
Chemotherapy
... can occur which prevent the drugs from binding to the protein, leading to resistance to these types of drugs. Drugs used in ... Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment ... Resistance is a major cause of treatment failure in chemotherapeutic drugs. There are a few possible causes of resistance in ... drug-to-drug interactions, genetics, and obesity, which have major impacts on the actual concentration of the drug in the ...
PELP-1
... and colon neoplasms. PELP1 signaling contributes to hormonal therapy resistance. Altered localization of PLP1 contributes to ... Since PELP1 lacks known enzymatic activity, drugs that target PELP1 interactions with other proteins should have clinical ... AR, PELP1 and Src form constitutive complexes in prostate neoplasms model cells that exhibit androgen independence. Cytoplasmic ... Since PELP1 interacts with histone modifications and epigenetic enzymes, drugs targeting epigenetic modifier enzymes may be ...
Melanoma
"Counteracting Drug Resistance in Melanoma". 2015. Archived from the original on 2015-02-04. "Bristol drug cuts death risk in ... Melanoma is a type of neuroectodermal neoplasm. There are four main types of melanoma: Other histopathologic types are: Mucosal ... "GSK melanoma drugs add to tally of U.S. drug approvals". Reuters. May 30, 2013. Archived from the original on September 24, ... Rebecca, Vito W.; Herlyn, Meenhard (2020). "Nongenetic Mechanisms of Drug Resistance in Melanoma". Annual Review of Cancer ...
Waldenström macroglobulinemia
ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Based on this study, the Food and Drug Administration approved ibrutinib for use in Waldenström macroglobulinemia in 2015. ... When primary or secondary resistance invariably develops, salvage therapy is considered. Allogeneic stem cell transplantation ... "FDA approves zanubrutinib for Waldenström's macroglobulinemia". U.S. Food and Drug Administration (FDA). 1 September 2021. ...
Prostate cancer
"Drug resistance in metastatic castration-resistant prostate cancer". Nature Reviews. Clinical Oncology. 8 (1): 12-23. doi: ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... "FDA approves new drug for advanced prostate cancer" (Press release). Food and Drug Administration. 15 May 2013. Archived from ... based National Prostate Cancer Coalition stated that prostate cancer drugs were outnumbered seven to one by breast cancer drugs ...
Periodontal disease
It may be beneficial to limit the use of systemic drugs, since bacteria can develop antimicrobial resistance and some specific ... induced Genetic/developmental disorders Specific infections Inflammatory and immune conditions Reactive processes Neoplasms ... Local drug deliveries in periodontology has gained acceptance and popularity compared to systemic drugs due to decreased risk ... Systemic drug delivery in conjunction with non-surgical therapy may be used as a means to reduce the percentage of the ...
Radiation therapy
A third technique is to enhance the radiosensitivity of the cancer by giving certain drugs during a course of radiation therapy ... Daly MJ (March 2009). "A new perspective on radiation resistance based on Deinococcus radiodurans". Nature Reviews. ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... Examples of radiosensitizing drugs include cisplatin, nimorazole, and cetuximab. The impact of radiotherapy varies between ...
List of skin conditions
... drug-induced lichen planus, lichenoid drug eruption) Drug-induced lupus erythematosus Drug-induced nail changes Drug-induced ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... Electrical burn Equestrian perniosis Erythema ab igne (fire stains, toasted skin syndrome) Erythrocyanosis crurum Favre- ... Chemotherapy-induced hyperpigmentation Drug-induced acne Drug-induced angioedema Drug-related gingival hyperplasia Drug-induced ...
History of cancer chemotherapy
... but by using different drugs concurrently it would be more difficult for the tumor to develop resistance to the combination. ... A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951. PMID 14850976. Li, MC; Hertz ... Farber met resistance to conducting his studies at a time when the commonly held medical belief was that leukemia was incurable ... This drug was pivotal in the cure of testicular cancer. Subsequently, Eve Wiltshaw and others at the Institute of Cancer ...
MALT lymphoma
As proton-pump inhibition can suppress infection, any treatment with this class of drug should be ceased 2 weeks prior to ... ISBN 0-7817-5007-5. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... "Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy ... or a combination of all three drugs. The final results of this study, including the later addition of a rituximab-alone arm, ...
Murine respirovirus
Drug Discovery. 6 (12): 975-90. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472. S2CID 583709. Albini A, Marchisone C, Del ... There are multiple explanations for such resistance. Not all cancer cells have cell entry receptors for the virus and not all ... Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal ... Simon AY, Moritoh K, Torigoe D, Asano A, Sasaki N, Agui T (December 2009). "Multigenic control of resistance to Sendai virus ...
Epithelioid sarcoma
Aldoxorubicin is a new version of doxorubicin that is designed to safely deliver a higher dose of the drug directly to the ... Cancer stem cells are a small population of tumor cells characterized by general chemo-resistance, the ability to self-renew, ... a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study ... Two of these inhibitory proteins that have been studied recently are CTLA-4 and PD1, and drugs targeting these proteins are in ...
Stem cell marker
January 2002). "Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells ... Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... December 2003). "The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and ... Staud F, Pavek P (April 2005). "Breast cancer resistance protein (BCRP/ABCG2)". The International Journal of Biochemistry & ...
Cyclophosphamide
Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... Hall AG, Tilby MJ (September 1992). "Mechanisms of action of, and modes of resistance to, alkylating agents used in the ... 2010), "Oxazaphosphorines: new therapeutic strategies for an old class of drugs", Expert Opin Drug Metab Toxicol, 6 (8): 919- ... increasing both pharmacologic and toxic effects of the drug; alternatively, drugs that inhibit hepatic microsomal enzymes (e.g ...
Polycystic ovary syndrome
... which is a strong risk factor for insulin resistance, although insulin resistance is a common finding among women with PCOS in ... Rasgon N (June 2004). "The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence". ... androgen-secreting neoplasms, and other pituitary or adrenal disorders, should be investigated. History-taking, specifically ... Insulin resistance can be observed in both normal weight and overweight people, although it is more common in the latter (and ...
Toothache
Examples include neoplasms of the gingival or alveolar mucosa (usually squamous cell carcinoma),: 299 conditions which cause ... An estimated 10% of all antibiotic prescriptions are made by dentists, a major factor in antibiotic resistance. They are often ... Since many cases of toothache are inflammatory in nature, over the counter non-steroidal anti-inflammatory drugs (NSAIDs) may ... Consequently, acute or chronic maxillary sinusitis can be perceived as maxillary toothache, and neoplasms of the sinus (such as ...
Chronic myelogenous leukemia
... neither dasatinib nor nilotinib could overcome drug resistance caused by one particular mutation found to occur in the ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... The first of this new class of drugs was imatinib mesylate (marketed as Gleevec or Glivec), approved by the US Food and Drug ... "FDA approves new orphan drug for chronic myelogenous leukemia" (Press release). US Food and Drug Administration. September 4, ...
Estrogen (medication)
"Drugs@FDA: FDA-Approved Drugs". Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens II: ... This is due to its synthetic nature and its resistance to metabolism in certain tissues such as the intestines, liver, and ... "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli, David G. Johns (eds.). ... Velayudham LS, Farrell GC (2003). "Drug-induced cholestasis". Expert Opin Drug Saf. 2 (3): 287-304. doi:10.1517/eods.2.3. ...
Folliculin
April 2002). "Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome". Cancer ... June 2016). "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding". Nature Communications. 7: ... "Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription". ... cosegregation of kidney neoplasms with BHD cutaneous lesions was observed in 3 families with a family history of kidney tumors ...
Megestrol acetate
Unlisted Drugs. Pharmaceutical Section, Special Libraries Association. 1965. Bakke OM, Wardell WM, Lasagna L (May 1984). "Drug ... The improved potency of MGA compared to medroxyprogesterone acetate may be due to increased resistance to metabolism of MGA ... Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Urologe (in German). 10 (3): 117-9. ... Drugs with unknown mechanisms of action, Glucocorticoids, Hormonal antineoplastic drugs, Hormonal contraception, Pregnanes, ...
PANACREAS
Particularly, resistance to conventional therapeutics and high propensity to metastasize were taken into account when choosing ... This represents the conditio sine qua non for the finding of drugs that can be effective against PDAC. The most promising ... have close to no impact on the course of this aggressive neoplasm. Therefore, virtually all of the patients diagnosed with PC ... strong proof-of-concept activity of any of these compounds will be a green light for proceeding to an Investigational New Drug ...
Bovhyaluronidase azoximer
Infobox drug articles with non-default infobox title, Infobox drug articles without a structure image, Chemical articles ... malignant neoplasms, acute renal failure, age under 18 years (no clinical study data available). It should also be used with ... increasing resistance to denaturation and the action of inhibitors while preserving the enzymes native structure and activity, ... CS1 errors: missing periodical, Orphaned articles from May 2021, All orphaned articles, Drugs with non-standard legal status, ...
E2F1 Induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells
Jong-In Park, PhD | Professor | Medical College of Wisconsin
SciELO - Brazil - Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis...
Keywords: Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy; Drug resistance; Drug monitoring, neoplasm; Receptor ... Leukemia, myelogenous, chronic, BCR-ABL positive; Drug resistance; Drug monitoring, neoplasm; Receptor Protein-Tyrosine Kinases ... Imatinib resistance is generally due to the appearance of clones expressing mutated forms of BCR-ABL, in which the amino acid ... Some imatinib resistance mechanisms may be overcome by dose escalation.(41,42) A retrospective analysis was carried out for ...
CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting...
Keywords: Ovarian Neoplasms, Multicellular Spheroids, CDC25A, Drug Resistance, Cell Cycle, and Molecular Targeted Therapy ... Loss-of-function studies showed that CDC25A promoted cisplatin-resistance and paclitaxel-resistance and inhibited the drug- ... Sun Y, Li S, Yang L, Zhang D, Zhao Z, Gao J, Liu L. CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular ... Sun Y, Li S, Yang L, Zhang D, Zhao Z, Gao J, Liu L. CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular ...
Biblio | Page 30 | Linus Pauling Institute | Oregon State University
Drug Resistance, Neoplasm. Parasramka MA, Ho E, Williams DE, Dashwood RH. 2012. MicroRNAs, diet, and cancer: new mechanistic ... Colonic Neoplasms. Parasramka MA, W Dashwood M, Wang R, Abdelli A, Bailey GS, Williams DE, Ho E, Dashwood RH. 2012. MicroRNA ... Neoplasms. Parasramka MA, Ho E, Williams DE, Dashwood RH. 2012. MicroRNAs, diet, and cancer: new mechanistic insights on the ...
Subject: basic-leucine zipper transcription factors / Subject term: basic-leucine zipper transcription factors - PubAg Search...
... lung neoplasms; lungs; multiple drug resistance; neoplasm cells. Abstract:. ... Lung adenocarcinomas exhibit chemoresistance ... induced resistance; leaves; necrosis; pathogens; tobacco; tomatoes; transgenic plants. Abstract:. ... Nonhost resistance as a ... Herb-induced liver injury is a leading cause of drug-induced liver injury in China and its incidence is also increasing ... Egcg maintained nrf2-mediated redox homeostasis and minimized etoposide resistance in lung cancer cells ...
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral...
Neoplasm Staging. dc.subject. Prognosis. dc.subject. Immunohistochemistry. dc.subject. Drug Resistance, Neoplasm. ... Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral ... PURPOSE: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-positive metastatic breast cancers ... Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral ...
MICHAEL W. N. DEININGER - Research - Faculty Profile - The University of Utah
Current work in my lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, ... My scientific focus is leukemia, specifically myeloproliferative neoplasms (MPN) including CML, chronic myelomonocytic leukemia ... drug resistance and new molecular therapies in leukemia. My work describing the selective effects of imatinib on CML cells ...
Herpes Zoster Clinical Presentation: History, Physical Examination, Complications of Herpes Zoster
... also may occur during suppression of host resistance by neoplasms, by cytotoxic drugs, and, possibly, by radiation therapy. ... Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. Anesth Analg. 1998 Oct. ... Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010 Sep. 24(3 ... Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy ...
OPUS at UTS: Search - Open Publications of UTS Scholars
5 Drug Resistance, Neoplasm * 4 Antineoplastic Agents * 4 Cell-Derived Microparticles * 4 Neoplasms ... Microparticles derived from drug-resistant cells regulate miR-503 and PYK2 to promote migration and invasion in breast cancer. ... Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy?. Callaghan, R; Luk, F; Bebawy, M. ... Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Lu, JF; Luk, F; Gong ...
Molecular mechanisms of drug resistance<...
Neoplasms Medicine & Life Sciences 24% * Oligonucleotide Array Sequence Analysis Medicine & Life Sciences 11% ... Drug resistance can occur at many levels, including increased drug efflux, drug inactivation, alterations in drug target, ... Drug resistance can occur at many levels, including increased drug efflux, drug inactivation, alterations in drug target, ... Drug resistance can occur at many levels, including increased drug efflux, drug inactivation, alterations in drug target, ...
Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. - NextBio article
Drug Resistance, Neoplasm Humans Neoplasms Substances Antimetabolites, Antineoplastic Cytarabine Deoxycytidine Kinase Cytidine ... The acquired resistance in U937R cells was followed by increase in cytidine deaminase (CDA) activity, decrease in DCK activity ... 1.3 microM). The resistance in carcinomas was associated with higher CDA activity and lower influx when compared to araC ... Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Takuya Ohta, Hiroki Hori, ...
Cancer-associated fibroblasts-derived gamma-glutamyltransferase 5 promotes tumor growth and drug resistance in lung...
Taken together, our study illuminates that high level of GGT5 in CAFs contributes to cancer cell survival and drug resistance, ... Moreover, high expression of GGT5 in CAFs enhanced the drug resistance of cancer cells by increasing intracellular glutathione ... Lung cancer is a highly aggressive neoplasm with an unfavorable survival [1]. Non-small cell lung cancer (NSCLC) is the most ... Figure 4. Increased GGT5 in CAFs promotes the drug resistance of LUAD cells. (A) Apoptosis cells of A549 and LAC1 cells treated ...
After uncovering cause of drug resistance in leukemia, researchers find way to overcome it - STAT
... and blastic plasmacytoid dendritic cell neoplasm (BPDCN) sometimes become resistant to the targeted drug tagraxofusp. Cancer, ... An account of the discovery of the true source of resistance to the drug - and the identification of a drug that may overcome ... After uncovering cause of drug resistance in leukemia, researchers find a way to overcome it ... After uncovering cause of drug resistance in leukemia, researchers find way to overcome it. ...
MeSH Browser
Drug Resistance, Antineoplastic Neoplasm Drug Resistance Resistance, Antineoplastic Agent Resistance, Antineoplastic Drug NLM ... Drug Resistance [G07.690.773.984] * Drug Resistance, Microbial [G07.690.773.984.269] * Drug Resistance, Multiple [G07.690. ... DRUG RESISTANCE NEOPL. Entry Term(s). Antibiotic Resistance, Neoplasm Antineoplastic Agent Resistance Antineoplastic Drug ... Drug Resistance, Neoplasm Preferred Concept UI. M0028386. Scope Note. Resistance or diminished response of a neoplasm to an ...
Drug Discovery Unit - Research Outputs - Discovery - the University of Dundee Research Portal
NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, ... Prediction of drug penetration in tuberculosis lesions. Sarathy, J. P., Zuccotto, F., Hsinpin, H., Sandberg, L., Via, L. E., ... The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Patterson, S., Wyllie, S., Norval ... Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania. Wyllie, S., Roberts, A. J., Norval, S., ...
An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant...
Previously, we derived two drug-resistant breast cancer sublines (tamoxifen- and fulvestrant-resistant cell lines) from the ... In the current study, to further define molecular characteristics of acquired antiestrogen resistance we constructed an ... performed genome-wide mRNA and microRNA profiling to identify differential molecular pathways underlying acquired resistance to ... However, employing a systems biology approach to better understand the complexities underlying drug resistance phenotypes in ...
School of Respiratory Therapy - Research output - Taipei Medical University
IMSEAR at SEARO: Search
Laurentian University | Faculty Profiles
in Breast Cancer Metastasis and Drug Resistance, 2nd Edition (A. Ahmad, ed.) Springer Medical Publishers, New York. ... He also provides lectures for sessions on Molecular Diagnostics, Immunology, Haematology, Haematological Neoplasms, and ... Guo, B., Tam, A., Santi, S.A., Parissenti, A.M. (2016) Role of autophagy and lysosomal drugsequestration in acquired resistance ... His research expertise is in the area of molecular pharmacology, with a particular emphasis on chemotherapy drug resistance in ...
Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance | Molecular Cancer | Full Text
Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta. 2014;431:255-9. ... Have been identified as mediators of drug resistance, the exact mechanisms of drug resistance, cross-talk among different ... CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol. 2019;70: ... CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy. Leuk Res. 2019;85:106198. ...
Kenneth H Cowan - Research output - Research Nebraska
New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory ... Glutathione S-transferases and drug resistance. Morrow, C. S. & Cowan, K. H., 1990, In: Cancer Cells. 2, 1, p. 15-22 8 p.. ... Glutathione S-transferase and drug resistance.. Cazenave, L. A., Moscow, J. A., Myers, C. E. & Cowan, K. H., 1989, In: Cancer ... The phenomenon of pleiotropic drug resistance.. Myers, C., Cowan, K., Sinha, B. & Chabner, B., 1987, In: Important advances in ...
HuGE Navigator|HuGE Literature Finder|PHGKB
Department of Biological and Biomedical Sciences - Projects
- ResearchOnline
Investigating immune cell "macrophage" driven drug resistance in Acute Myeloid Leukaemia. Williams, M., Guzman, M. & Wheadon, H ... MACRESIST: Investigating immune cell "macrophage" driven drug resistance in Acute Myeloid Leukaemia. Williams, M. ... Macrophage driven therapy resistance in AML: from macrophage subset characterisation to the potential for therapeutic ...
FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells - Fingerprint -...
Colleges - Grants - Augusta University Research Profiles
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE. Liu, K., Colson, Y., ... Neoplasms 12% * Tumor Hypoxia: Molecular Studies and Clinical Exploitation. Terris, D. J., GIACCIA, A., BLOCH, D., Bouley, D., ... Understanding Mechanisms of Resistance to Anti-angiogenic Treatments. Arbab, A. S. & ARBAB, A. S. ...
Increased vimentin mRNA expression in MCF-7 breast cancer cell line after repeated endoxifen-treatment - Fingerprint -...
Ronan Swords - Publications
- Oregon Health & Science University
Drug Resistance 47% * Neoplasms 41% * Crystallography 37% * Proto-Oncogenes 30% 62 Scopus citations ... Burke, A. C., Swords, R. T., Kelly, K. & Giles, F. J., Mar 2011, In: Expert Opinion on Emerging Drugs. 16, 1, p. 85-103 19 p.. ... Mahalingam, D., Mita, A., Sankhala, K., Swords, R., Kelly, K., Giles, F. & Mita, M. M., 2009, In: Current Drug Targets. 10, 10 ... Apostolidou, E., Swords, R., Alvarado, Y. & Giles, F. J., 2007, In: Drugs. 67, 15, p. 2153-2171 19 p.. Research output: ...
MetastasisHumansCancerSurvivalMelanomaPathwaysTherapyPhenotypeMolecularReceptorsChemotherapyMyeloproliferativeMicroenvironmentLeukemiaMultidrugMutationCarcinomaTamoxifenInsulin resistanceSERDRisk FactorsEvasionDoxorubicinCombination with cytotoxic drugsMethylationMechanismsProteinsImmunologyResistantPeptide
Metastasis1
- It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE . (bvsalud.org)
Humans1
- Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. (nih.gov)
Cancer30
- Sun Y, Li S, Yang L, Zhang D, Zhao Z, Gao J, Liu L. CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting Cell Cycles. (jcancer.org)
- Loss-of-function studies showed that CDC25A promoted cisplatin-resistance and paclitaxel-resistance and inhibited the drug-induced apoptosis in ovarian cancer MCS. (jcancer.org)
- Resistance to chemotherapy limits the effectiveness of anti-cancer drug treatment. (qub.ac.uk)
- Resistance to chemotherapy is believed to cause treatment failure in over 90% of patients with metastatic cancer, and resistant micrometastic tumour cells may also reduce the effectiveness of chemotherapy in the adjuvant setting. (qub.ac.uk)
- This review focuses on molecular mechanisms of drug resistance that operate to reduce drug sensitivity in cancer cells. (qub.ac.uk)
- Moreover, high expression of GGT5 in CAFs enhanced the drug resistance of cancer cells by increasing intracellular glutathione and reducing the intracellular reactive oxygen species in cancer cells. (aging-us.com)
- Taken together, our study illuminates that high level of GGT5 in CAFs contributes to cancer cell survival and drug resistance, indicating that GGT5 may be a promising therapeutic target in lung adenocarcinoma. (aging-us.com)
- Lung cancer is a highly aggressive neoplasm with an unfavorable survival [ 1 ]. (aging-us.com)
- The drug works like a guided missile with a poison payload: The IL3 portion carries the toxin to cancer cells and essentially gives them a case of diphtheria. (statnews.com)
- However, employing a systems biology approach to better understand the complexities underlying drug resistance phenotypes in cancer continues to represent a significant challenge to the field. (biomedcentral.com)
- Previously, we derived two drug-resistant breast cancer sublines (tamoxifen- and fulvestrant-resistant cell lines) from the MCF7 breast cancer cell line and performed genome-wide mRNA and microRNA profiling to identify differential molecular pathways underlying acquired resistance to these important antiestrogens. (biomedcentral.com)
- By integrating miRNA-related network, gene/miRNA expression and text-mining, the current study provides a computational-based systems biology approach for further investigating the molecular mechanism underlying antiestrogen resistance in breast cancer cells. (biomedcentral.com)
- Unfortunately, tumor cells often develop resistance to endocrine therapy [ 1 ], representing a major obstacle limiting the success of breast cancer treatment. (biomedcentral.com)
- In breast cancer, alterations in expression of miRNAs appear to play important roles in drug resistance [ 7 , 8 ] and thus may represent new therapeutic targets. (biomedcentral.com)
- His research expertise is in the area of molecular pharmacology, with a particular emphasis on chemotherapy drug resistance in breast and ovarian cancer. (laurentian.ca)
- Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand the mechanisms that lead to treatment resistance. (researchgate.net)
- Methods: Methylation differences between the drug-resistance cervical cancer cell, SiHa, and its derived oxaliplatinresistant S3 cells were detected by methylation specific microarray. (ncku.edu.tw)
- Conclusions: These results suggest that global methylation is associated with the development of drug resistance and could serve as a biomarker and therapeutic target for drug resistance in cervical cancer. (ncku.edu.tw)
- Recognizing resistance or susceptibility to the current standard cisplatin and paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical cancer. (biomedcentral.com)
- Class III tubulin is a common target for taxane chemotherapy and its overexpression has been associated with resistance in patients with NSCLC, breast cancer and gastric cancer treated with tubulin binding agents [ 13 ]. (biomedcentral.com)
- Cancer drugs often fail due to the emergence of clinical resistance. (oncotarget.com)
- Hyaluronic acid-modified multifunctional Q-graphene for targeted killing of drug-resistant lung cancer cells. (cdc.gov)
- Considering the urgent need to explore multifunctional drug delivery system for overcoming multidrug resistance, we prepared a new nanocarbon material Q-Graphene as a nanocarrier for killing drug-resistant lung cancer cells. (cdc.gov)
- Overall, a highly promising multifunctional nanoplatform was developed for tracking and monitoring targeted drug delivery for efficiently killing drug-resistant cancer cells. (cdc.gov)
- The model organism D. melanogaster is studied to find ground-breaking research in neurology, sleep, cancer, and drug discovery. (cram.com)
- In the context of public health, oral cancer represents one of the most aggravating conditions of oral health, representing 5% of all neoplasms. (bvsalud.org)
- The detailed structure may guide the development of new drugs that modify JAK activity, amplifying or dampening cell responses, with potential applications in cancer therapies. (edu.au)
- Above: The structure of SOCS1 (red) bound to a JAK protein (beige) could inform the development of new drugs to treat cancer. (edu.au)
- In particular, overactive JAK signalling is linked to the development of cancer-like conditions called myeloproliferative neoplasms (MPNs) - which include polycythemia vera, essential thrombocythemia and primary myelofibrosis - as well as certain acute childhood leukaemias . (edu.au)
- If we could design a drug that inhibits SOCS1, this might boost anti-cancer immune responses, potentially improving anti-cancer immunotherapies. (edu.au)
Survival4
- Clearly, if drug resistance could be overcome, the impact on survival would be highly significant. (qub.ac.uk)
- The incidence, mortality, and survival of leukemia depends on the diagnosis, prognosis, as well as natural history of neoplasms arising from the malignant transformation of hemopoietic stem cells or progenitor cells in the bone marrow [ 3 ]. (biomedcentral.com)
- Background The presence of resistance to chemotherapy is associated with poor tumor response and patient survival in a variety of tumors. (utmb.edu)
- While checkpoint inhibitors have demonstrated survival benefit and are currently approved in the front-line and second-line settings, primary and secondary resistance is common. (port.ac.uk)
Melanoma1
- Methods Using a nude rat human xenograft model of extremity melanoma,we analyzed tumors for glutathione (GSH), the main protein in the melphalan resistance pathway. (utmb.edu)
Pathways4
- As a clinician-scientist with a translational research focus I am heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance and new molecular therapies in leukemia. (utah.edu)
- We demonstrated that dramatically different molecular mechanisms underlie progression to resistance to tamoxifen (henceforth, MCF7-T) and fulvestrant (henceforth, MCF7-F) and also identified specific genes and biochemical pathways associated with SERM- and SERD-resistance. (biomedcentral.com)
- Endometriosis is characterized by progesterone resistance and hyperactivity of the AKT and MAPK pathways. (webpediatrica.com)
- The atomic-level structure of SOCS1 binding to its partner protein JAK could guide the development of drugs that alter disease-causing cell signalling pathways, and may have applications for treating some blood cancers, including leukaemias . (edu.au)
Therapy10
- Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. (scielo.br)
- Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. (cam.ac.uk)
- PURPOSE: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm). (cam.ac.uk)
- Combined detection and genotyp- performed before antimicrobial drug vey to assess the impact of chikungu- ing of Chikungunya virus by a specifi c therapy based on amoxicillin/clavu- nya fever and Aede s infestation levels. (cdc.gov)
- Currently, the three classes of commonly used drugs for adjuvant endocrine therapy are selective estrogen receptor modulators (SERMs, e.g., tamoxifein), selective estrogen receptor down-regulators (SERDs, e.g., fulvestrant), and aromatase inhibitors (AIs). (biomedcentral.com)
- Attempts to modulate resistance in conjunction with systemic chemotherapy have been limited by the toxicity of combined therapy, particularly gastrointestinal or hematopoetic toxicity. (utmb.edu)
- This study explored systemic modulation of resistance in conjunction with intra-arterial regional therapy to determine if tumor responses to melphalan could be improved with acceptable toxicity. (utmb.edu)
- BCR-ABL kinase domain mutation analysis, evaluation of drug interactions, and compliance to therapy are recommended before the start of second-line TKI therapy. (medscape.com)
- OBJECTIVES OF THE ASSESSMENT: The Ministère de la Santé et des Services sociaux (MSSS) asked the Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) to evaluate the efficacy of photodynamic therapy using porfimer sodium for its approved oncological indications. (bvsalud.org)
- Additionally, diabetic patients got more oxygen therapy (32 hours, p 0.05), injectable antiviral drugs (161, p 0.05), and low molecular weight heparin (105, p 0.05) than non-diabetics. (medrech.com)
Phenotype2
- In particular, if the development of drug resistance is associated with changes in DNA methylation, then demethylation might reverse the resistance phenotype. (ncku.edu.tw)
- The drug-resistance cells were treated with demethylation agent to see if the resistance phenotype were reversed. (ncku.edu.tw)
Molecular1
- He also provides lectures for sessions on Molecular Diagnostics, Immunology, Haematology, Haematological Neoplasms, and Autoimmune Diseases for the Northern Ontario School of Medicine. (laurentian.ca)
Receptors1
- The drug binds to its receptors in the cytoplasm by passing through the cell membrane, and the drug-receptor complex enters the cell nucleus. (firedrug.com)
Chemotherapy8
- Tumours may be intrinsically drug-resistant or develop resistance to chemotherapy during treatment. (qub.ac.uk)
- This will facilitate the future development of rational combined chemotherapy regimens, in which the newer targeted therapies are used in combination with cytotoxic drugs to enhance chemotherapy activity. (qub.ac.uk)
- Inhibition of p-glycoprotein by anti-angiogenic TKI might contribute to the beneficial effect of these small molecules, when combined with chemotherapy, in counteracting acquired drug resistance. (springernature.com)
- Conclusions Modulation of resistance in conjunction with regional chemotherapy allows for improved tumor responses with minimal toxicity. (utmb.edu)
- Interestingly, high III beta tubulin expression was associated with chemotherapy resistance and fewer responses [5/20 (25%)] compared to lower III β-tubulin expression [15/23 (65.2%)] ( p = 0.008). (biomedcentral.com)
- ERCC1 N118 N and MDR1 G2677 T polymorphism also proved of prognostic significance for disease progression, while overexpression of III β-tubulin was positively correlated with chemotherapy resistance. (biomedcentral.com)
- Resistance to chemotherapy is widely recognized as one of the major factors that limit therapeutic efficacy and influence patient outcomes. (biomedcentral.com)
- Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy [electronic resource]. (who.int)
Myeloproliferative2
Microenvironment1
- Current work in my lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets and developing more specific signal transduction inhibitors. (utah.edu)
Leukemia2
- Dana-Farber scientists had a perfectly reasonable theory of why acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) sometimes become resistant to the targeted drug tagraxofusp. (statnews.com)
- To this end, we analyzed whole-exome sequencing data of eight chronic lymphocytic leukemia (CLL) patients that developed resistance upon BCL2-inhibition by venetoclax. (researchgate.net)
Multidrug1
- Multidrug resistance. (nebraska.edu)
Mutation1
- Ponatinib or asciminib are treatment options for patients with T315I mutation and for those with resistance to or intolerance of several TKIs. (medscape.com)
Carcinoma1
- Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. (illumina.com)
Tamoxifen1
- Based on the integrative network, we extracted "substructures" (network clusters) representing the drug resistant states (tamoxifen- or fulvestrant-resistance cells) compared to drug sensitive state (parental MCF7 cells). (biomedcentral.com)
Insulin resistance2
- Recent studies have demonstrated that increased serum GGT level predicted the advanced histological hepatic injury, insulin resistance and other chronic disease [ 6 , 7 ]. (aging-us.com)
- Study on Uric Acid as Biomarker for Insulin Resistance in Type 2 Diabetic Mellitus. (aimdrjournal.com)
SERD1
- ESR1 mutational mediated resistance may be overcome by selective ER degraders (SERD). (cam.ac.uk)
Risk Factors3
- Only a small percentage of cases have none of the identified risk factors (male homosexuality, intravenous drug abuse, Haitian origin, and perhaps hemophilia A). To avoid a reporting bias, physicians should report cases regardless of the absence of these factors. (cdc.gov)
- From medical records and antiepileptic drug (AED) use, Mbizvo looked for risk factors that may have contributed to these epilepsy-related deaths. (medscape.com)
- Preventive measures include control of risk factors, drugs to make blood less likely to clot, and sometimes surgery or angioplasty to open blocked arteries. (msdmanuals.com)
Evasion1
- Drug resistance can occur at many levels, including increased drug efflux, drug inactivation, alterations in drug target, processing of drug-induced damage, and evasion of apoptosis. (qub.ac.uk)
Doxorubicin2
- The exposure of ovarian adenocarcinoma TEC to the TKIs sunitinib or sorafenib was found to abrogate resistance (proliferation and motility) to doxorubicin and paclitaxel in vitro, increasing intracellular drug accumulation. (springernature.com)
- Additionally, doxorubicin (DOX) as a model drug was loaded on the surface of Q-Graphene via p-p stacking. (cdc.gov)
Combination with cytotoxic drugs1
- No beneficial effect was observed in combination with cytotoxic drugs that are not p-glycoprotein substrates. (springernature.com)
Methylation5
- As luck would have it, a drug capable of blocking such methylation, named azacytidine, already exists. (statnews.com)
- KCNQ1OT1 polymorphism rs35622507 and methylation status of KCNQ1OT1 promoter influence the drug resistance to L-OHP. (cdc.gov)
- The reversion of the drug-resistance might then be feasible if the association between abnormal DNA methylation and the development of drug-resistance could be identified. (ncku.edu.tw)
- Targeted methylation of one of the identified locus in normal cell is expected to recapitulate the development of resistance and a two-component reporter system is adopted to monitor the increase of DNA methylation in live cells. (ncku.edu.tw)
- Finally, we found that methylation of the target gene Casp8AP2 is sufficient to increase drug resistance in different cells. (ncku.edu.tw)
Mechanisms5
- Integrating multiple biomarkers in prospective trials may improve outcome prediction and ET resistance mechanisms' identification over a single biomarker. (cam.ac.uk)
- Acquired resistance is a particular problem, as tumours not only become resistant to the drugs originally used to treat them, but may also become cross-resistant to other drugs with different mechanisms of action. (qub.ac.uk)
- Exploiting different mechanisms of action, a novel triple drug delivery system of 5-fluorouracil, curcumin, and piperine co-loaded human serum albumin nanoparticles (5FU-CUR-PIP-HSA-NPs) was developed via the self-assembly method for suppressing breast tumor. (bvsalud.org)
- The current paper reviews the mechanisms of TEC chemoresistance and shows the role of p-glycoprotein in mediating such resistance. (springernature.com)
- understand the mechanisms that lead to treatment resistance. (researchgate.net)
Proteins2
- This can manifest through mutations in target proteins that selectively exclude drug binding whilst retaining aberrant function. (oncotarget.com)
- New medicines for these conditions are needed, and we envisage that a drug designed to mimic the SOCS1 protein to switch off JAK proteins might be a more effective treatment," Dr Kershaw said. (edu.au)
Immunology1
- Despite great advances in immunology, microbiology, and drug development, TB remains a significant public health challenge. (medscape.com)
Resistant3
- We made experimental models of cells resistant to the drug and found that they, too, didn't lose CD123," says the study's senior author Andrew Lane, M.D., Ph.D., director of the BPDCN Center at Dana-Farber. (statnews.com)
- There is evidence that TEC are more resistant to chemotherapeutic drugs, substrates of ATP-binding cassette (ABC) transporters. (springernature.com)
- Despite advances in available therapies, children with drug-resistant and relapsed neuroblastoma have a dismal outlook with. (hrb.ie)
Peptide1
- Here, we address the important question of potential resistance to stapled peptide inhibitors. (oncotarget.com)